Loading
CAR-T Cell Therapy Research / Monoclonal and Polyclonal Antibodies Research · Journal article
Blood Cancer Discovery · August 13, 2026
The material analysed did not support any firm read.
This is an editorial summary of a study by Merz et al. examining sequencing of CAR T and bispecific antibody therapy in multiple myeloma. The commentary reports that CAR T-first sequencing conferred a progression-free survival advantage, driven by CAR T's early benefit; full data, effect sizes, and confidence intervals are not provided in this source.
Journal article. Recipients of chimeric antigen receptor T-cell (CAR T) and/or bispecific antibody therapy in multiple myeloma, including those who received both modalities sequentially..
CAR T therapy used first showed a clear progression-free survival advantage over bispecific antibody-first sequencing Study included more than 600 recipients of CAR T and/or bispecific antibody therapy Outcomes with both modalities were similar when following progression after the converse modality, indicating the advantage was driven by CAR T up-front benefits
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If confirmed in the primary study, a CAR T-first sequencing strategy may offer superior progression-free survival in multiple myeloma compared to bispecific antibody-first approach. Clinicians should refer to the full Merz et al. report for effect sizes, confidence intervals, and subgroup analyses to inform treatment sequencing decisions.
This is a summary/editorial commentary on another study, not a primary research report; the source does not provide original data, effect sizes, confidence intervals, p-values, or sample descriptions needed to grade the evidence.
Quoted from the source exactly as published.
If confirmed in the primary study, a CAR T-first sequencing strategy may offer superior progression-free survival in multiple myeloma compared to bispecific antibody-first approach. Clinicians should refer to the full Merz et al. report for effect sizes, confidence intervals, and subgroup analyses to inform treatment sequencing decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Summary: In this issue of Blood Cancer Discovery, Merz and colleagues study more than 600 recipients of chimeric antigen receptor T-cell (CAR T) and/or bispecific antibody therapy in multiple myeloma with an emphasis on patients who received both modalities sequentially. They find a clear progression-free survival advantage when CAR T therapy was used first; importantly, because outcomes with both modalities were similar when following progression after the converse modality, this advantage was driven by CAR T therapy’s up-front benefits. See related article by Merz et al, p. XX.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.